Business Context and Reporting Period
Company: Regentis Biomaterials Ltd. (RGNT)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Regentis is a regenerative medicine company developing tissue repair solutions, primarily focused on its lead product candidate, GelrinC. GelrinC is a cell-free, off-the-shelf hydrogel implant for treating painful injuries to articular knee cartilage. The product holds a CE mark in Europe (since 2017) but has not yet received FDA approval in the United States. The company is currently conducting a pivotal clinical trial in the U.S. and Europe to support a Pre-Market Approval (PMA) submission.
Key Financial Metrics
| Metric (USD in thousands) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Income (Loss) | $(13,648) | $4,801 | $(4,132) |
| Operating Loss | $(6,968) | $932 | $(1,931) |
| Cash and Cash Equivalents (Year End) | $7,378 | $229 | $345 |
| Accumulated Deficit | $(55,794) | $(42,146) | $(46,947) |
| Net Cash Used in Operating Activities | $(1,375) | $(641) | $(1,220) |
| Net Cash Provided by Financing Activities | $8,524 | $525 | $325 |
Note: 2024 net income was driven by a one-time Horizon 2020 grant and favorable changes in the fair value of convertible notes and warrant liabilities. 2025 results reflect significant non-cash share-based compensation expenses and fair value adjustments related to the IPO.
Material Changes vs. Prior Period
- Initial Public Offering (IPO): In December 2025, the company completed its IPO, issuing 1,250,000 ordinary shares at $8.00 per share, raising gross proceeds of approximately $10 million. This significantly improved liquidity, increasing cash balances from $229,000 in 2024 to $7.378 million in 2025.
- Equity Conversion: Upon the IPO, all outstanding convertible preferred shares (Series A, B, C, D-1, D-2) and convertible notes were converted into ordinary shares. Consequently, temporary equity was eliminated from the balance sheet.
- Expense Volatility: General and Administrative (G&A) expenses surged to $6.6 million in 2025 from $0.7 million in 2024. This increase was primarily due to $5.4 million in non-cash share-based compensation and a $500,000 special bonus to the CEO following the IPO.
- Financial Income/Expense: Net financial expense increased to $6.7 million in 2025 from financial income of $3.9 million in 2024. This shift was driven by a $4.9 million expense related to the change in fair value of convertible notes and $1.7 million in share-based payment expenses related to warrants granted to lenders.
Guidance, Outlook, and Risks
- Clinical Outlook: The company is midway through its pivotal clinical trial for GelrinC. As of the filing date, 47 of the required 80 patients have been recruited and treated, with 43 completing the two-year follow-up. The company expects to complete patient recruitment by the end of Q2 2026 and submit a PMA application by the end of 2027.
- Liquidity and Going Concern: Despite the IPO proceeds, the company's audited financial statements contain an explanatory paragraph regarding substantial doubt about its ability to continue as a going concern. Management believes current cash resources will fund operations through February 2027. Additional funding will be required to commercialize the product.
- Key Risks:
- Regulatory Approval: Failure to obtain FDA approval for GelrinC would prevent U.S. commercialization.
- Geopolitical Instability: Operations are based in Israel. The filing highlights risks related to the ongoing conflict in the Middle East, including potential disruptions to operations, supply chains, and the mobilization of key personnel for military service.
- Capital Requirements: The company has no revenue and expects to incur continued losses. Failure to raise additional capital on acceptable terms could force the curtailment of operations.
- Third-Party Reliance: The company relies on third-party contract manufacturers and suppliers for raw materials and clinical trial execution.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that cash reserves ($7.4 million) will sustain operations through February 2027 given the high burn rate.
- Clinical Trial Progress: Monitor the recruitment status of the remaining 33 patients for the pivotal trial and the timeline for the PMA submission.
- Geopolitical Exposure: Assess the potential impact of the conflict in Israel on the company's R&D facilities, supply chain, and key personnel availability.
- Going Concern Status: Review the auditor's report regarding the "substantial doubt" qualification and management's specific plans to mitigate this risk.
- Related Party Transactions: Review the terms of short-term loans and warrants granted to directors and officers (e.g., CEO, Board members) during the pre-IPO bridge financing period.